IVT GBS 06
Alternative Names: Hexavalent group B streptococcal vaccine; IVT-GBS-6; IVT-Group B Strep-06; IVTGBS06Latest Information Update: 01 Oct 2024
At a glance
- Originator Inventprise
- Class Conjugate vaccines; Streptococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Streptococcal infections
Most Recent Events
- 24 Sep 2024 Inventprise plans a phase I/II trial for Streptococcal infections (Prevention) in USA and South Africa in October 2024 (IM, Injection) (NCT06611371)
- 29 Nov 2021 IVTGroupBStrep 06 is available for licensing as of 29 Nov 2021. https://www.inventprise.com/?page_id=2182
- 29 Nov 2021 Preclinical trials in Streptococcal infections (Prevention) in USA (Parenteral) as of November 2021 (Inventprise pipeline, November 2021)